BMS Has High Hopes on Eliquis Follow-Up with Less Bleeding Risks as Patent Loss Looms

Shoichiro Ogawa, Head of Innovative Medicines Business Unit, BMS Japan Bristol Myers Squibb is looking to launch an Eliquis (apixaban) follow-on, which is expected to carry lower bleeding risks, in 2025-2026, about the same time as anticipated generic entries for...read more